CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay…

Posted: May 15, 2022 at 2:13 am

VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company’s Scientific Board of Advisors. In addition, Dr. Jay Lalezari has agreed to serve as an outside Scientific Advisor to the Company.

Read this article:
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay...

Related Posts